companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2023
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -53,000 and a net result of DKK 5,000 compared with DKK 4,000 the year before. Equity amounted to DKK 1,788,000. The solvency ratio was 98.2%.
- Gross Profit
- -53,000 kr.
- Profit/Loss
- 5,000 kr.
- Equity
- 1,788,000 kr.
- Total Assets
- 1,821,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -53 t. | 5 t. | 1.8 mio. | - |
| 2022 | - | -6 t. | 4 t. | 1.8 mio. | - |
| 2021 | - | - | -37 t. | 1.8 mio. | - |
| 2020 | - | - | -108 t. | 1.8 mio. | - |
| 2019 | - | - | -398 t. | 8.9 mio. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of June 30, 2023, Kristine Aachmann Bethe has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 30, 2023, Tomas Haagen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2022. Gross profit came to DKK -6,000, and the net result was DKK 4,000.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.